Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

130.72 +1.05 (+0.81%)
Official Closing Price Updated: 7:00 PM EDT, Jun 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 17,243,071
Open 130.17
Bid (Size) 125.23 (1)
Ask (Size) 132.45 (2)
Prev. Close 129.67
Today's Range 129.09 - 131.20
52wk Range 99.14 - 133.10
Shares Outstanding 2,531,374,696
Dividend Yield 2.23%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AbbVie Inc. Dividend Stock Analysis - Saturday, June 22
Here are some highlights from a detailed, quantitative analysis AbbVie Inc. stock. Let's take a closer look at various factors, such as the stock's value and dividend. 
Via Talk Markets
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments. 
Via Benzinga

Performance

YTD
+15.44%
+15.44%
1 Month
-0.28%
-0.28%
3 Month
+4.32%
+4.32%
6 Month
+21.45%
+21.45%
1 Year
+14.07%
+14.07%

More News

Read More
3 Top Penny Stocks to Skyrocket Your Wealth in 2024
Via InvestorPlace
Cracking The Code: Understanding Analyst Reviews For Merck & Co
Via Benzinga
Competitor Analysis: Evaluating Merck & Co And Competitors In Pharmaceuticals Industry
Via Benzinga
Merck & Co Unusual Options Activity For June 14
Via Benzinga
How Is The Market Feeling About Merck & Co?
Via Benzinga
Market Whales and Their Recent Bets on MRK Options
Via Benzinga
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
Via FinancialNewsMedia
Topics Death
Exposures Death
Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
Via Benzinga
Exposures COVID-19
FDA Approves Merck's Pneumococcal Vaccine As First Shot Designed For Adults
Via Benzinga
Exposures Product Safety
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
From FN Media Group LLC
Via GlobeNewswire
U.S. FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
From Merck & Co., Inc.
Via Business Wire
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma
From Merck & Co., Inc.
Via Business Wire
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines
Via MarketBeat
Exposures COVID-19
3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street
Via The Motley Fool
3 Crazy Good Stocks to Buy With $500 Right Now
Via InvestorPlace
3 Penny Stocks to Buy if You Want to Spend Less and Earn More
Via InvestorPlace
3 High-Yield Dividend Stocks to Collect Impressive Payouts Year After Year
Via InvestorPlace
Healthcare And Biotech Investing: Breakthroughs In The Treatment Of Cancer At ASCO
Via Talk Markets
From $10k to $100k: 3 Stocks With the Potential for Amazing Returns
Via InvestorPlace
Nike, Merck, General Motors, And More: CNBC's 'Final Trades'
Via Benzinga
Moderna Says Combination Flu And Covid Vaccine Beat Out Rivals From Sanofi, GSK
Via Investor's Business Daily
Exposures COVID-19
Why Moderna Stock Is a No-Brainer Buy Right Now
Via The Motley Fool
3 Reasons to Buy Moderna Stock
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.